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Main points 
• Axons damaged by the expression of pathological tau protein primed OPCs to 
enhance differentiation following focal demyelination. 
• This in vivo priming is maintained after isolation and prolonged in vitro culturing of 
OPCs. 
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Abstract 
Oligodendrocyte progenitor cell (OPC) differentiation is an important therapeutic target to 
promote remyelination in multiple sclerosis (MS). We previously reported 
hyperphosphorylated and aggregated microtubule-associated protein tau in MS lesions, 
suggesting its involvement in axonal degeneration. However, the influence of pathological 
tau-induced axonal damage on the potential for remyelination is unknown. Therefore, we 
investigated OPC differentiation in human P301S tau (P301S-htau) mice, both in vitro and in 
vivo following focal demyelination. In 2 month-old P301S-htau mice, which show 
hyperphosphorylated tau in neurons, we found atrophic axons in the spinal cord in the 
absence of prominent axonal degeneration. These signs of early axonal damage were 
associated with microgliosis and an upregulation of IL-1β and TNFα. Following in vivo focal 
white matter demyelination we found that OPCs differentiated more efficiently in P301S-
htau mice than wild type (Wt) mice. We also found an increased level of myelin basic 
protein within the lesions, which however did not translate into increased remyelination 
due to higher susceptibility of P301S-htau axons to demyelination-induced degeneration 
compared to Wt axons. In vitro experiments confirmed higher differentiation capacity of 
OPCs from P301S-htau mice compared to Wt mice-derived OPCs. Since the OPCs from 
P301S-htau mice do not ectopically express the transgene, and when isolated from newborn 
mice behave like Wt mice-derived OPCs, we infer that their enhanced differentiation 
capacity must have been acquired through microenvironmental priming. Our data suggest 
the intriguing concept that damaged axons may signal to OPCs and promote their 
differentiation in the attempt at rescue by remyelination. 
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Introduction 
Remyelination is the most efficient regenerative process of the adult CNS and is vital for 
functional recovery in demyelinating diseases like multiple sclerosis (MS) (Franklin, 2012). 
Following demyelination oligodendrocyte progenitor cells (OPCs), which are abundant in the 
adult CNS, migrate towards the lesion where they proliferate and differentiate into 
myelinating oligodendrocytes (Crawford, 2013). Remyelination becomes less efficient in the 
later stage of MS in part due to a failure of OPC differentiation (Franklin and ffrench-Constant, 
2008; Kuhlmann, 2008; Wolswijk, 1998). Failure of remyelination is a major contributor to the 
accumulation of axonal and neuronal degeneration that characterizes the progressive stage 
of the disease in which clinical deficits accumulate over time (Bjartmar, 2000; De Stefano, 
2001). The axonal degeneration observed after toxin-induced demyelination in mice 
depleted of OPCs is prevented by the transplantation of exogenous OPCs that restore 
remyelination capacity (Irvine and Blakemore, 2008). Thus, enhancing remyelination, and 
particularly OPC differentiation, is an important therapeutic strategy to promote 
neuroprotection in the progressive stage of MS. Injured axons in the MS lesion initially show 
a focal mitochondrial dysmorphism and axonal swelling (Nikic, 2011) which subsequently 
develops into axonal truncation with terminal ovoids (Trapp, 1998). Injured axons in MS 
lesions accumulate amyloid precursor protein (APP), which is detectable only in axons with 
impaired fast axonal transport (Ferguson, 1997; Sherriff, 1994). The impairment of axonal 
transport may result from the recently demonstrated presence in MS lesions of 
hyperphosphorylated tau (Anderson, 2008). 
 
Tau is a microtubule-associated protein that when abnormally hyperphosphorylated loses 
its function of promoting microtubule stabilization altering axonal transport as observed in 
primary cultures (Bramblett, 1993; Mellone, 2013), in human IPSC-derived neurons (Iovino, 
2015), and in P301S-htau mice (Bull, 2012). The presence of hyperphosphorylated 
filamentous tau is a feature of several neurodegenerative disorders such as Alzheimer’s 
disease, Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17T), 
progressive sopranuclear palsy, and others that are collectively designated as tauopathies 
(Spillantini and Goedert, 2013). The dysfunction of tau is sufficient to cause 
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neurodegeneration, as shown in FTDP-17T that is caused by mutations in the MAPT gene 
(Spillantini, 1998; Hutton, 1998). 
The inflammatory attacks that repeatedly occur in MS are likely to result in tau post-
translational alterations, since an inflammatory environment clearly promotes tau 
hyperphosphorylation in animal studies (Bhaskar, 2010; Birch, 2014; Bellucci, 2004). In addition 
hyperphosphorylated insoluble tau has been observed in several cases of primary and 
secondary progressive MS but not in an example of relapsing remitting MS (Anderson, 2008; 
Anderson, 2009; Anderson, 2010). In a mouse model of chronic inflammation-driven 
demyelination the levels of insoluble tau positively correlate with axonal loss (Anderson, 
2008), suggesting that the conversion of soluble to insoluble tau may contribute to axonal 
pathology in the progressive stage of MS. The phosphorylation status of tau is finely 
regulated by several kinases and phosphatases (Hanger, 2009), and its hyperphosphorylation 
can be also physiological, for example during fetal brain development, hypothermia, and 
hibernation (Spillantini and Goedert, 2013). Thus, the presence of hyperphosphorylated tau 
can be reversible and is not necessarily a precursor to insoluble oligomeric forms. Reversible 
injury may also be a sign of early axonal degeneration in demyelinated lesions, as 
demonstrated in a mouse model of inflammation-driven demyelination where some axons 
with focal swelling and dysmorphic mitochondrial recover spontaneously (Nikic, 2011). Thus, 
myelin can rescue damaged axons by stabilising the cytoskeleton, releasing trophic factors, 
and providing a source of energy such as lactate (Franklin, 2012; Lee, 2012). Conversely, axons 
also signal to oligodendrocytes and OPCs, for example by releasing glutamate that in the 
presence of the growth factor neuregulin promotes myelination and remyelination 
(Lundgaard, 2013; Demerens, 1996). However, whether the signals from damaged axons may 
also affect remyelination remains unclear. 
 
In this study we investigated whether axonal damage associated with tau pathology affects 
remyelination. In particular we investigated OPC differentiation and remyelination following 
a toxin-induced focal demyelination in P301S-htau mice that express the human tau 
transgene under the pan-neuronal promoter Thy1.2 (Allen, 2002). We also confirmed the 
behaviour of OPCs isolated from P301S-htau mice in vitro. 
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Methods and Materials and Methods 
 
Antibodies 
Primary antibodies: HT7 (mouse, Thermo Scientific, 1:1000), AT8 (mouse, Thermo Scientific, 
1:1000), NF200 (rabbit, Sigma-Aldrich, 1:1000), APP (clone 22C11, mouse, Millipore, 
1:1000), Iba1 (rabbit, Wako, 1:5000), CD11b (rat, Serotec, 1:1000), Olig2 (rabbit, Millipore, 
1:1000), NG2 (rabbit, Millipore, 1:1000) APC (mouse, clone CC1, Chalbiochem, 1:200), SOX2 
(goat, Santa Cruz, 1:300), MBP (rat, Serotec, 1:300 in IHC, 1:500 for ICC, and 1:2000 for WB), 
βIII-tubulin (Rabbit, AbCam, 1:500), β-actin (mouse, Sigma-Aldrich, 1:10000). Biotin-
conjugated secondary antibodies (Vector, 1:1000), Alexa-conjugated secondary antibodies 
(Molecular Probes, 1:1000). HRP-conjugated secondary antibodies (1:5000): anti-mouse and 
anti-rabbit (GE), anti-rat (Vector). 
 
Animals 
Control Wt (C57Bl/6S OlaHsd; Harlan) and homozygote P301S-htau transgenic mice (kindly 
provided by Dr Michel Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK) 
expressing under the Thy1.2 promoter the shortest human tau isoform with four repeats no 
N-terminal inserts and with the P310S mutation (Allen, 2002), were kept in a 12 h light/dark 
cycle with water and food ad libitum (R105-25, Safe). In each experiment we used the same 
ratio of female and male animals for Wt and P301S-htau mice. All procedures were 
performed in accordance with the UK Animal (Scientific Procedures) Act 1986 for the 
welfare of laboratory animals and were approved by the Cambridge University local ethical 
committee. 
 
Focal demyelination 
Under anaesthesia with isoflurane 7-8 week-old mice received 1 μl of 1% lysolecithin (L-a-
lysophosphatidylcholine) (Sigma-Aldrich) dissolved in sterile PBS into the ventral funiculus of 
the spinal cords at the level of T12-13 (Zhao, 2006a). The injection was performed with a 10 
μl Hamilton syringe, fitted with a pulled glass capillary, at a rate of approximately 1 μl/min. 
For pain relief mice received an injection of buprenorphine (0.02 mg/kg, s.c.) at the 
beginning of the procedure. 
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Oligodendrocyte precursor cell (OPC) cultures 
OPCs were isolated from either 1 or 10-12 day-old mice (male and females) using A2B5-
conjucated microbeads positive sorting as previously described with some modifications 
(Windrem, 2004) (see supplementary material). This isolation protocol yielded highly 
enriched OPC cultures with almost undetectable microglial and neuronal cells and with 4.8% 
± 0.72 of astrocytes found after 4 days of proliferation. 
 
Migration assay: directly after isolation OPCs were placed on the top chamber of transwell 
(8 μm pores, Millopore, UK) in growth factor-free OPC medium, while the bottom chamber 
was filled with OPC medium supplemented with two-fold concentration of growth factor 
cocktail. After 12 h incubation at 37°C, we quantified the number of Hoechst 33258 (1 
μg/ml, Sigma-Aldrich) positive cells that crossed the transwell mash. 
Proliferation assay: after 36h of seeding, OPCs were incubated with the thymidine analogue 
5-ethynyl-2'-deoxyuridine (EdU, 10 μM final concentration, Invitrogen) for 3h at 37°C and 
subsequently fixed and stained with the Click-iT kit (Invitrogen) conjugated with Alexa 488. 
Cell death and differentiation assay: when reaching 50% confluence, 4-5 days after seeding, 
OPCs were incubated with growth factor-free OPC medium which was replaced with fresh 
growth factor-free OPC medium after two days. After two more days cells were fixed and 
stained for either DNA fragmentation (TUNEL technology, In Situ Cells Death detection kit, 
Roche) to assess cell death or, for MBP and Olig2, to quantify the number of mature 
oligodendrocytes. 
 
Immunohistochemistry and Immunocytochemistry 
Tissues and cell cultures were prepared for immunostaining as previously described with 
some modifications (Brelstaff, 2015) (see supplementary material). 
 
APC immunohistochemistry: sections on slides were incubated for 30 min at RT with antigen 
retrieval reagent (Sigma-Aldrich). Following cell permeabilization with 1% Triton X-100 in 
TBST (TBS with 0.05% Tween-20), tissue non-specific staining was block for 30 min with 10% 
normal donkey serum (NDS) in a 0.25% Triton X-100-TBST. Non-specific background was 
blocked with IgG solution from the MOM kit (Vector) 1:25 in TBST for 1h at RT. Sections 
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were then first incubated with APC (CC1 clone, 1:200 in TBST with 5% NDS) for 1h at RT, 
followed by the exposure to the secondary antibody (Donkey anti-mouse (anti-IgGb), Alexa 
488, 1:1000) for 1h at RT. Tissue was then treated as previously described above. 
 
In situ hybridization 
The proteolipid protein (PLP) probe was created for in situ hybridisation procedure as 
previously described (Sim, 2002). Cryostat sections of 12 μm thickness mounted on poly-l-
lysine coated glass slides were incubated with the riboprobes overnight at 58°C. The excess 
unbound labelled probes were removed by washing three times at 65 C with 1× Saline-
sodium citrate (150 mM NaCl, 15 mM Sodium citrate, pH 7) supplemented with 50% 
formamide and 0.1% Tween 20 solution. Sections were further washed twice with maleic 
buffer (50 mM maleic acid, pH 7.5, 250 mM NaCl and 0.1% Tween 20), then incubated with 
a solution of blocking reagent (2%, Roche) and 20% sheep serum made in maleic buffer at 
RT, followed by overnight incubation in alkaline phosphatase conjugated antibody at 4 C in a 
humidified chamber. After washing with maleic buffer five times for 10 min, the signal was 
visualised by incubating the slides with staining buffer containing NBT/BCIP (Roche, Lewes, 
UK) using a standard protocol. 
 
Toluidine blue staining, ranking analysis, and oil red O staining 
Tissue blocks of spinal cord of mice perfused with 4% glutaraldehyde diluted in PBS were 
processed through osmium tetroxide, dehydrated, and embedded in TAAB resin (TAAB 
Laboratories, Aldermaston, UK). Alkaline toluidine blue dye (0.5% Toluidine Blue+ 0.5% 
Borax) (Sigma-Aldrich) was applied on semi-thin (1μm) sections and heated with a Bunsen 
flame for 10 sec before washing with tap water (Zhao, 2006a). 
Ranking analysis was performed on toluidine blue stained sections containing similar sized 
lesions by a researcher blinded to the sample identity as described previously (Ibanez, 2004). 
In brief, sections from different mice were compared by ranking with the higher score to the 
lesion that contained less demyelinated axons. Thus, this method refrained from assigning a 
value representing the proportion of remyelinated axons. The same rank was assigned to 
sections that contained similar amounts of demyelinated axons.  
Oil red O stain kit (MasterTech) was used on 12 μm PFA-fixed tissue sections prepared as 
described above. 
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Western blotting 
Cells from OPCs cultures were incubated with RIPA buffer (25 mM tris pH 7.4, 150 mM NaCl, 
1% triton-x 100, 1% Na deoxycholate, 0,1% SDS, 1 mM EDTA, 10% Glycerol) supplemented 
with protease (cOmplete, Roche) and phosphatase (Sigma-Aldrich) inhibitor cocktails on ice 
for 20 min. Homogenates were centrifuged at 2000 g for 10 min and proteins in the 
supernatants were denatured in Laemmli buffer at 95°C for 7 min. Otherwise, OPCs cultures 
were incubated with 2.5% perchloric acid followed by dialysis and dephosphorylation with 
alkaline phosphatase (Roche) as previously described (Iovino, 2015). Samples were resolved 
in 4-12% SDS-PAGE gels (Invitrogen) and blotted on PVDF membrane (Merk). Membranes 
were blocked with 5% w/v skimmed milk dissolved in TBS containing 0.5% Tween (TBS-T) 
and incubated overnight at 4°C with primary antibody diluted in TBST supplemented with 
5% bovine serum albumin. Following incubation for 2h at RT with HRP-conjugated 
secondary antibody diluted (1:5000) in 5% Milk TBST, membranes were visualized with ELC 
plus (GE). Recombinant human tau isoforms (tau ladder, Sigma-Aldrich) were used as 
positive control for the identification of the human transgene.  
 
ELISA 
One whole spinal cord was homogenized with a FastPrep-24 homogenizer (MP Biomedicals) 
(2x10 sec, 5,500 rpm) in a 5 x volume of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, and 5 
mM EDTA) supplemented with protease and phosphatase inhibitor cocktails. Suspensions 
were centrifuged at 18,000 g for 10 min, and supernatants used to detect cytokines with a 
multiplex ELISA plate (Multi Spot Assay system, Pro-inflammatory Panel 1 kit, MSD, USA). 
Results were normalized for the protein concentration of each sample. 
 
RT-PCR 
OPCs cultures were harvested with RTL lysis buffer, passed through the QIAshredder column 
(Qiagen), and the RNA extracted with the RNeasy columns (Qiagen, Crawley, UK). RNA was 
extracted from human brain in the same way. We loaded 500 ng of RNA of each sample for 
amplification with OneStep RT-PCR (Qiagen). To detect human tau we amplified cDNA from 
exon 9 (forward primer: 5′ CTCCAAAATCAGGGGATCGC 3’) 
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 to exon 12 (reverse primer: 5′ TTTTTATTTCCTCCGCCAG 3′), at the following PCR conditions: 
50°C for 30 min, 95°C for 15 min, 94 °C for 30 sec, 65°C for 30 sec, 72°C for 1 min for 40 
cycles. This primer pair produces separate bands from tau mRNAs with 3 (461 bp) or 4 
repeats (552 bp) (Anfossi, 2011). mRNA from human brain was used as positive control. To 
detect mouse GAPDH as loading control we used the following primers: forward primer: 5′ 
TTCCAGTATGACTCTACCC 3’, and reverse primer: 5′ ATGGACTGTGGTCATGAGCCC 3′, at the 
following PCR conditions: 50°C for 30 min, 95°C for 15 min, 94 °C for 30 sec, 61°C for 30 sec, 
72°C for 1 min for 30 cycles. 
 
Imaging analysis 
All imaging analyses were carried out with ImageJ (1.49).  
For the quantification either cell density or staining intensity we analysed 4-5 slides for each 
animal. The lesion in lysolecithin-injected spinal cords was identified as the area of white 
matter with substantially higher density of Hoechst-positive nuclei. The contour of the 
lesion drawn in the blue channel was over-imposed on the other channels before counting 
the cell number or measuring staining intensity. 
 
Statistical analysis 
All imaging analyses were carried out with ImageJ (1.49).  
Values are expressed as means ± SEM. Statistical analyses for significant differences were 
performed with unpaired t-test for all the results except the ranking analysis data that were 
analysed with Mann-Whitney test using GraphPad Prism 5.0 software (GraphPad Software, 
Inc., San Diego, CA, USA). The criterion for statistical significance was p < 0.05.
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Results 
Early signs of axonal pathology in the spinal cord of P301S-htau mice 
The expression of the human tau transgene in P301S-htau mice rapidly increases in the first 
two weeks of life to plateau at four-five weeks of age in association with the appearance of 
abnormal hyperphosphorylation and filamentous tau (Scattoni, 2010; Delobel, 2008). 
Consistently, in the ventral funiculus of two month-old P301S mice virtually every axon was 
immunoreactive for HT7 (phosphorylation-independent human tau specific antibody 
recognizing the transgene), while several axons were also positive for AT8 immunostaining 
(phosphorylation-dependent human and mouse tau antibody) (Fig 1A). Despite the early 
development of tau pathology in P301S-htau mice, significant neuronal loss has been 
detected only from three months of age (Hampton, 2010; Yang, 2015). Interestingly, in 2 
month-old P301S-htau mice toluidine blue staining of the ventral funiculus (embedded in 
resin) revealed a marked change in axonal calibre distribution and occasional myelin figures 
(concentrically layered myelin without axon) suggestive of Wallerian degeneration (Fig 1, 
red arrows in C). Compared to Wt, in P301S-htau mice the proportion of larger-calibre axons 
(≥ 4 μm
2
) was significantly reduced while that of smaller-calibre axons (≤ 2 μm
2
) was 
significantly increased (Fig 1B). The total axonal density in P301S-htau mice was not 
significantly different from Wt mice (Fig 1C). Neurofilament staining with NF200 antibody 
showed that axons in the ventral funiculus of the spinal cord were consistently smaller and 
more condensed in P301S-htau mice compared to Wt mice (Fig1D).  
We next investigated whether the axons in the ventral funiculus of the spinal cord were 
immunoreactive for APP, which accumulates in degenerating axons (Ferguson, 1997; Sherriff, 
1994). Two month-old P301S-htau mice displayed a limited number of APP positive axons 
that were mostly in the marginal areas, which are normally populated by larger-calibre 
axons (Fig 1A). Conversely, axonal degeneration was increased in 5 month-old P301S-htau 
mice where several APP positive axons were present (Fig1A). These data suggest that in 
young adult P301S-htau mice, axons exhibit signs of pathology without overt axonal 
degeneration. 
 
Early microgliosis in P301S-htau mice 
Two month-old P301S-htau mice showed a marked microgliosis in the spinal cord (Fig 2A), 
as well as significantly increased levels of the inflammatory cytokines IL-1β and TNFα (Fig 2B 
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and C), which was consistent with previously published work on older (5 month-old) P301S-
htau mice (Bellucci, 2004). 
CD11b- and Iba1-immunoreactive microglia/macrophages in 2 month-old P301S-htau mice 
exhibited mostly ramified appearance with thick processes, despite occasional clustering 
and few amoeboid-shaped cells. In contrast, most microglial cells from 5 month-old P301S-
htau mice were amoeboid with short processes and a propensity to cluster (Supplementary 
Fig 1). These data indicate an inflammatory response to early axonal pathology in P301S-
htau mice. 
 
Increased density of OPC differentiatedion oligodendrocytes after focal demyelination in 
P301S-htau mice 
We next investigated the response to demyelination in P301S-htau mice. Following a 
lysolecithin injection into the ventral funiculus of young adult mice, which induces a focal 
area of primary demyelination, OPCs migrate and proliferate around and within the lesion 
for the first few days. OPCs then start to differentiate into new myelin sheath forming 
oligodendrocytes at around 10 days post lesion (dpl)-induction, such that at 14 dpl 
remyelination is well underway and usually complete at 21 dpl (Zhao, 2005). We quantified 
the number of OPCs and oligodendrocytes within the lesion (identified as the area of white 
matter with substantially higher density of Hoechst-positive nuclei). Adenomatous polyposis 
coli (APC) protein immunostaining and proteolipid protein (PLP) in situ hybridization, 
markers of mature oligodendrocytes, demonstrated that 14 dpl P301S-htau mice compared 
to Wt mice exhibited significantly higher density of oligodendrocytes within the lesion (Fig 
3A and B). Whereas the number of OPCs, identified as Sox2 (highly expressed in reactive 
OPCs) and Olig2 (an oligodendroglial linage marker) double positive cells, was the same 
within lesions in Wt and P301S-htau mice (Fig 3A and D). Mutant and Wt mice had the same 
density of mature oligodendrocytes (Olig2
+
/APC
+
 cells) and OPCs (Sox2
+
/Olig2
+
) in 
unlesioned white matter (Fig 3B and D). Quantification was inclusive of most of the 
oligodendroglial lineage, since the sum of APC
+
/Olig2
+
 and Sox2
+
/Olig2
+
 cells closely 
mirrored the total number of Olig2
+
 cells (Fig 1B, D and E). Due to a reduction of axonal 
calibre average in naïve P301S-htau mice compared to Wt mice, we investigated whether 
the lesion size in the two mouse lines differed. The lesion areas were identical between 
Page 11 of 40
John Wiley & Sons, Inc.
GLIA
 12
mutant and Wt mice (Supplementary Fig 2), suggesting that the changes in oligodendrocytes 
density was not due to shrinkage of the lesion size in P301S-htau mice.  
 
Remyelination and axonal degeneration 
We next investigated the degree of remyelination. Figure 4A shows that at 14 dpl myelin 
basic protein (MBP) was significantly more abundant within the lesion of P301S-htau than 
Wt mice (Fig 4A and B). As MBP immunostaining fails to distinguish myelin sheaths from 
myelin debris, we stained the sections with Oil O-Red, which within the lesion strongly 
highlights lipid droplets representing myelin debris. Both mutant and Wt mice presented 
similar degrees of myelin debris within the lesions (Fig 4D and E), suggesting that the 
presence of higher levels of MBP in P301S-htau mice was due to an increase of new myelin 
sheaths. To investigate further the degree of remyelination we analysed the presence of 
remyelinated axons in semi-thin sections of resin embedded tissue. The myelin thickness 
visualized by toluidine blue staining allows differentiation of axons that have been 
remyelinated (thin myelin sheath, red arrows) from normally myelinated axons that have 
not been demyelinated by lysolecithin (thick myelin sheath, white arrows) (Blakemore, 1974). 
Ranking analysis of the extent of remyelination did not reveal a significant difference 
between transgenic and control mice (Fig 4D and F). We did, however, find a marked 
reduction of axons within the lesion of P301S-htau compared to Wt mice, which 
represented a 35% reduction in NF200 positive axons (Fig 4A and C). We also observed a 
greater amount of APP immunoreactivity in the lesion in P301S-htau compared to Wt mice 
(Fig 4D and G). However, in non-lesioned spinal cords of P301S-htau mice there was only a 
limited number APP positive axons and the axonal density in the ventral funiculus was not 
significantly different between transgenic and Wt mice (Fig 1A and C).  
These data demonstrate that following demyelination P301S-htau mice within the lesion 
develop mature oligodendrocytes that are able to produce more myelin sheaths compared 
to Wt mice. However, the reduced number of axons available for myelination in the lesion in 
P301S-htau compared to Wt mice renders it difficult to unequivocally determine differences 
in the remyelination capacity between transgenic and Wt mice. 
 
OPCs isolated from P301S-htau mice showed enhanced differentiation capacity 
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The increased axonal degeneration observed in P301S-htau mice after demyelination may 
have influenced the rate of OPC differentiation. Thus, we compared the properties of OPCs 
derived from mutant and Wt mice in an in vitro system where axons are absent. OPCs from 
mutant and Wt mice comparably migrated towards a higher concentration of growth factors 
(data not shown) and proliferated as measurement of the DNA integration of EdU over a 3h 
period (Fig 5A). In the presence of growth factors-free medium most OPCs either 
differentiate in oligodendrocytes or die by apoptosis (Miron, 2013). Following withdrawal of 
growth factors for 4 days, we found a similar number of TUNEL
+
 cells but a 2-fold increase of 
MBP
+
/Olig2
+
 mature oligodendrocytes in cultures derived from P301S-htau mice compared 
to those from Wt mice (Fig 5B, C, and D). This was corroborated by a 3-fold increase of MBP 
protein in extracts obtained from cultures derived from P301S-htau mice compared to Wt 
mice (Fig 5E and F).  
Next we asked how profoundly OPCs isolated from P301S-htau have been influenced by the 
presence of pathological tau in vivo. To this end, isolated OPCs from 10 day-old mice were 
cultured with growth factors for either 4 (direct differentiation) or 10 (differentiation after 
expansion) days before inducing differentiation. To ensure the presence of a comparable 
population between Wt and P301S-htau-derived OPCs after the in vitro cell expansion, we 
sorted for a second time cells with A2B5-conjugated microbeads (see Methods). Figs 5G and 
H show that OPCs isolated from P301S-htau mice retained the capacity to produce more 
MBP compared to those derived from Wt mice during differentiation after a prolonged cell 
expansion. 
These results demonstrated that OPCs from P301S-htau mice differentiate into mature 
oligodendrocytes more efficiently than those from Wt mice even in culture in the absence of 
axonal degeneration. Also OPCs isolated from P301S-htau mice retained this enhanced 
differentiation capacity even after a prolonged cells expansion. 
 
Human tau protein is not ectopically expressed or found in P301S-htau OPCs  
The expression of P301S-htau transgene is restricted to the nervous system by the use of 
Thy1.2 promoter that contains only the neuronal-specific element of the Thy1 promoter 
(Vidal, 1990; Caroni, 1997). However, to confirm that the transgene was not ectopically 
expressed in OPCs, we measured the expression of human tau in OPCs isolated from P301S-
htau mice and compared it to the total expression of P301S-htau mice and human brain 
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tissues (Fig 6 A). RT-PCR for 3-repeat (3R) and 4-repeat (4R) tau showed the presence of two 
bands in human brain (HB), one band corresponding to the transgene in P301S-htau mouse 
brain (MB), but no band was observed in OPC extracts. 
 
Compelling evidence demonstrates that an increasing variety of cell types release and 
uptake pathological tau (Clavaguera, 2015). Thus, we investigated the presence of human tau 
protein in isolated OPCs. Protein extracts from freshly isolated OPCs from P301S-htau mice 
showed no specific band when probed with HT7 antibody even after a prolonged exposure 
(Fig 6B). Also OPCs expressing NG2 (a proteoglycan expressed on the plasma membrane of 
OPCs) that were kept proliferating 48h after isolation from P301S-htau mice showed no 
immunoreactivity for HT7, which on the other hand was readily detected in dorsal root 
ganglion culture derived from P301S-htau mice (Fig 6C). 
Even though OPCs from P301S-htau mice contained no human tau, their functionality may 
be influenced by exposure to the transgenic protein in vivo, which has been shown to be 
released by tau-overexpressing neurons (de Calignon, 2012). To test this hypothesis, we 
exposed OPCs isolated from Wt mice to filamentous and hyperphosphorylated tau obtained 
by sarkosyl extraction of spinal cords of 5 month-old P301S-htau mice as previously 
described (Goedert and Jakes, 1990). A range of concentrations of sarkosyl-insoluble extracts 
(1.5, 7.5, 15 μg/ml) incubated for 4 days during the growth factor withdrawal phase failed to 
enhance the differentiation of Wt mice-derived OPCs (data not shown). These data suggest 
that the increased differentiation capacity of isolated P301S-htau OPCs is not dependent on 
the human transgene expression or spreading to these cells in vivo. 
 
The enhanced differentiation capacity of P301S-htau mice-derived OPCs is acquired  
We previously showed that in the brain of P301S-htau mice the human tau protein is 
present at low level at birth and rapidly increases up to 14 days of age (Scattoni, 2010). Thus, 
to assess the relationship between the level of transgene expression and OPC differentiation 
rate, we repeated the protocol on OPCs isolated one day after birth. In this new condition 
OPCs derived from P301S-htau mice differentiated into MBP positive cells bearing myelin 
sheath to a similar degree as Wt mice-derived OPCs (Fig 7A). Also MBP protein level in 
extracts from cultures of OPCs isolated from either P301S-htau or Wt mice following growth 
factor withdrawal were almost identical (Fig 7B). The expression pattern of MBP isoforms in 
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the cultures derived from newborn mice was different from those derived from older mice. 
Changes in the level of MBP isoform expression during the different stage of development 
have previously been described (Mathisen, 1993). 
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Discussion 
This work shows for the first time that axonal injury, due to the expression of pathological 
tau, promotes the differentiation of OPCs during remyelination.  
Most axons in the ventral funiculus of the spinal cord in P301S-htau mice expressed the 
human transgene and several exhibited hyperphosphorylated tau at 2 months of age. At this 
age P301S-htau mice displayed atrophic axons in the absence of a marked axonal 
degeneration, suggesting an early injury state (Fig 1). This is in line with the axonal transport 
impairment, both anterograde and retrograde, that we recently reported in vivo in the optic 
nerve of the P301S-htau mice, in vitro in dorsal root ganglion neuronal cultures and human 
IPS-derived neurons (Mellone, 2013; Iovino, 2015; Bull, 2012). Similar results were observed 
also by Ittner (2008) and colleagues in transgenic mice expressing human tau with the K369I 
mutation. Axonal transport impairment is also present in MS lesions (Ferguson, 1997), which 
may be linked to the presence of tau hyperphosphorylation that we have previously 
described (Anderson, 2008; Anderson, 2009; Anderson, 2010). In P301S-htau mice the early 
axonal injury was associated with microgliosis creating an inflammatory environment (Fig 2). 
By 5 months of age P301S-htau mice showed activated microglial cells that were mostly 
amoeboid-shaped and clustered (Supplementary Fig 1) (Bellucci, 2004). Similar microglial 
clustering is frequently found in early stages of MS white matter in the absence of 
demyelination, but associated with axonal injury identified as accumulation of APP and non-
phosphorylated neurofilament (Singh, 2013). To note, an inflammatory microenvironment is 
essential for an efficient remyelination, for example for the removal of myelin debris from 
the demyelinated lesions (Miron, 2013; Kotter, 2005; Ruckh, 2012). Importantly, the cytokines 
IL-1β and TNFα, which are upregulated in young P301S-htau mice compared to Wt mice (Fig 
2), are instrumental to the differentiation of OPCs and remyelination after a toxin-induced 
demyelination (Mason, 2001; Arnett, 2001; Arnett, 2003; Zhao, 2006b). Therefore, the 
inflammatory environment present in P301S-htau mice before lysolecithin injection may be 
responsible for the increased density of mature oligodendrocytesenhanced OPC 
differentiation (Fig 3). This increase of oligodendrocytes in P301S-htau mice compared to Wt 
mice may have resulted from either an enhanced recruitment of OPCs within the first few 
days after the lesion or from a more efficient OPC differentiation. However, dDespite the 
fact that enhanced OPC differentiation was specifically associated with an increase of myelin 
sheath, we were not able rigorously to compare the degree of remyelination between 
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transgenic and Wt mice due to an increased axonal degeneration in P301S-htau mice 
following lysolecithin injection (Fig 4). In fact although lysolecithin normally causes only 
limited axonal degeneration (Huang, 2012), lesions in P301S-htau mice showed a 35% 
reduction of NF200 positive axons and a significant increase of APP accumulation compared 
to Wt mice (Fig 4). This may be due to lysolecithin-induced depletion of myelin-derived 
trophic support to axons, which in the case of already damaged P301S-htau axons resulted 
in marked degeneration. Indeed Nikic (2011) and colleagues have described that in an 
experimental model of MS axons showing signs of injury such as swelling and dystrophic 
mitochondria, can recover if they retain the myelin wrapping. In order to determine 
whether the axonal degeneration observed in P301S-htau mice may have influenced the 
OPCs maturation in vivo, we investigated the functionality of OPCs isolated from 10-12 day 
old mice. Interestingly, we found that OPCs from P301S-htau mice more efficiently 
differentiated into mature oligodendrocytes with formation of the myelin membrane 
sheathsheets (Fig 5D-F). Further we demonstrated that this enhanced differentiation 
capacity of OPCs derived from P301S-htau mice is maintained after a 10-day cell expansion, 
representing about four cell replications (Fig 5G and H). This supports the in vivo data 
showing that the increased OPC differentiation in transgenic compared to Wt mice did not 
require the presence of axonal degeneration.  
We also excluded the possibility that the phenotype found in P301S-htau mice-derived OPCs 
was due ectopic expression or spreading of the human transgene into these cells (Fig 6). 
Thus we reasoned that OPCs from P301S-htau mice may be primed in vivo by a 
microenvironment that reacts to neuronal expression of the transgene. This hypothesis was 
further supported by absence of the enhanced differentiation capacity of OPCs isolated 
from one day-old P301S-htau mice when the level of transgene expression is limited (Fig 7A 
and B). Therefore the level of transgenic protein and the time that OPCs are exposed to the 
P301S-htau mice in vivo microenvironment are essential for their priming. 
 
We speculate that the hyperphosphorylation of tau induced by inflammatory attacks of the 
CNS in MS contributes to early axonal injury, which in turn may signal to OPCs to facilitate 
remyelination. In case remyelination fails, the hyperphosphorylation of tau may contribute 
to toxic oligomerization and fibril formation leading to the degeneration of axons driving the 
clinical symptoms of progressive MS where indeed hyperphosphorylated and aggregated 
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tau is present (Anderson, 2008). Future studies will investigate the specific molecules 
involved in the communication between axons and OPCs that leads to an improved 
maturation of oligodendrocytes in our model of tauopathy.
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Figure legends 
Figure 1. Early signs of axonal injury in the spinal cord of P301S-htau mice. Thoracic (T12-
T13) spinal cord sections taken from 2 month-old Wt and P301S-htau mice, were stained 
with antibodies or toluidine blue (A). Red arrows in toluidine blue stained sections point to 
myelin figures in P301S-htau mice. Myelin figures were absent in Wt mice. Quantification of 
axonal calibre distribution (B) and axonal density (C) in the ventral funiculus of 2 month-old 
Wt and P301S-htau mice measured in toluidine blue stained sections. Scale bars represent 
100 μm, if not otherwise indicated. Quantification of axonal calibre was obtained from three 
pictures of the ventral funiculus taken at 100x magnification from four P301S-htau and four 
Wt mice. Each picture contained 250-450 axons. Statistical analysis was performed between 
axons of Wt and P301S-htau mice with the same calibre range using unpaired t-test. NS = 
non-significant, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 
 
Figure 2. Early microgliosis in P301S-htau mice. Thoracic (T12-T13) spinal cord sections 
from 2 month-old Wt and P301S-htau mice were immunostained for microglial markers 
(Iba1 and CD11b) (A). Scale bars represent 100 μm, if not otherwise indicated. Protein 
extracts from the whole spinal cord of 2 month-old Wt and P301S-htau mice were assessed 
by ELISA for IL-1β (B) and TNFα (C). Data represent the mean ± SEM from four P301S-htau 
and four Wt mice. Statistical difference between Wt and P301S-htau mice was calculated 
using unpaired t-test. * = p ≤ 0.05, *** = p ≤ 0.001. 
 
Figure 3. Increased density of OPCs differentiatedion oligodendrocytes after focal 
demyelination in P301S-htau mice. Lysolecithin was injected in the ventral funiculus of 
thoracic (T12-13) spinal cords of 2 month-old Wt and P301S-htau mice. After 14 days from 
the injection tissues were collected, sectioned, and stained for oligodendrocyte (in situ 
hybridization for PLP, and immunofluorescence for APC) and OPCs markers (Olig2
+
/Sox2
+
 
cells) (A). Scale bars: 100 μm. Quantification of APC
+
/Olig2
+
 cells within and outside the 
lesioned white matter (B). Quantification of PLP mRNA
+
 cells within the lesioned white 
matter (C). Quantification of Sox2
+
/Olig2
+
 cells within and outside lesioned white matter (D). 
Quantification of total number of Olig2
+
 cells within and outside the lesioned white matter 
(E). Data represent the mean ± SEM from at least 6 animals per group. Statistical analysis of 
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cell number differences within the lesioned areas were calculated between Wt and P301S-
htau mice using unpaired t-test. * = p ≤ 0.05, ** = p ≤ 0.01. 
 
Figure 4. Remyelination and axonal degeneration. Lesioned spinal cords from 2 month-old 
Wt and P301S-htau mice 14 days after lysolecithin injection were sectioned and stained (A 
and D). In the toluidine blue stained images, red arrows point to examples of remyelinated 
axons, whereas white arrows point to axons that had not been demyelinated. Scale bars 
represent 100 μm, if not otherwise indicated. Quantification of MBP intensity within the 
lesioned area is calculated as % of non-lesioned white matter within the same section (B). 
Quantification of NF200 positive axons within the lesioned area (C). Quantification of Oli O 
Red staining intensity (marker of myelin debris) within the lesioned area is calculated as % 
of non-lesioned white matter within the same section (E). Ranking analysis (see Methods) of 
toluidine blue stained sections (F). Quantification of APP staining intensity within the 
lesioned area represented as % of grey matter within the same section (G). Data represent 
the mean ± SEM from at least 6 animals per group. Statistical analysis was performed 
between Wt and P301S-htau mice using Mann-Whitney test for the ranking score (F) and 
unpaired t-test for the other data (B, C, E, and G). * = p ≤ 0.05, ** = p ≤ 0.01. NS = non-
significant. 
 
Figure 5. OPCs isolated from P301S-htau mice showed enhanced differentiation. OPCs 
were isolated from P10-12 Wt and P301S-htau mice, and grown in medium with or without 
growth factors (see Methods). Quantification of OPCs proliferation was performed two days 
after isolation in the presence of growth factors by counting the number of cells that 
incorporated EdU (A). Quantification of cell death four days after growth factors withdrawal 
was performed by TUNEL staining (B). OPCs cultures were immunostained for MBP and 
Olig2 four days after growth factors withdrawal (C) and MBP
+
 cells were represented as % of 
Olig2
+
 cells (D). Protein extracts from OPCs cultured after four days of growth factors 
withdrawal were probed for MBP, Olig2, and β-actin (E) and bands intensity was 
represented as % of Wt cultures (F). OPCs isolated from P10-12 Wt and P301S-htau mice 
were grown in the presence of growth factors for either four (direct diff.) or ten days (diff. 
after expansion) before proteins were extracted to detect the MBP levels (G). Data 
represent the mean ± SEM from at least 4 (A, B, D) or 3 (F and H) independent experiments. 
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Statistical analysis performed between Wt and P301S-htau mice using unpaired t-test. * = p 
≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
 
Figure 6. Human tau protein is not ectopically expressed or found in P301S-htau OPCs. 
RNA extracted from OPC cultures 48h after isolation were probed for the presence of htau 
mRNA (A). Both Wt and P301S-htau OPCs showed no presence of htau. RNA extracts of 
P301S-htau mouse (MB) and human brain (HB) were used as positive control and show a 
strong 4R band, and 4R and 3R band tau respectively. Mouse GAPDH used as control shows 
that the amount of mRNA used was similar in all mouse samples (A). Protein extracts of 
OPCs cultures for 48h after isolation were dephosphorylated with alkaline phosphatase and 
probed for HT7 (anti-human specific phosphorylation-independent antibody) (B). No specific 
bands were stained in protein extracts of both Wt and P301S-htau OPCs culture. 
Recombinant human tau ladder was used as marker to identify the human tau bands using a 
lower exposure time compared to the cell extracts (ladder on the right). OPCs cultures for 
48h after isolation were immunostained with NG2 (plasma membrane marker of OPCs) and 
HT7 (C). No HT7 immunoreactivity was observed in NG2
+
 cells. Dorsal root ganglion (DRG) 
culture obtained from 2 month-old P301S-htau mice was used as positive control of HT7 
immunostaining in βIII-tubulin (Tubulin) neurons. Scale bars represent 50 μM. 
 
Figure 7. The enhanced differentiation capacity of P301S-htau OPCs is acquired. OPCs 
isolated from postnatal day 1 Wt and P301S-htau mice were subjected to the same 
differentiation protocol as described (A and B). Following four days of growth factors 
withdrawal cells were either fixed and immunostained for MBP and Olig2 (A) or lysed for 
protein extraction (B). Scale bars represent 100 μM. 
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Supplementary methods 
OPCs cultures 
Cortical hemispheres were finely chopped with springbow dissecting scissors and digested 
for 30 min at 37°C with papain (20 U/ml, Worthington, UK). After adding ovomucoid 
inhibitor (Worthington, UK), the tissue was gently triturated with fire-polished glass pipettes 
and subsequently passed through a 70 μm cell strainer. Only for tissue derived from 10-12-
day-old mice myelin debris was removed by centrifuging 3.5 mL of 90% isotonic Percoll (GE, 
Sweden) added to 11 mL of cell suspension for 20 min at 800 g. The myelin debris layer was 
removed and the pellet was washed once with HBSS solution (Invitrogen, UK). OPCs were 
incubated with A2B5-conjugated microbeads (Miltenyi Biotec, San Francesco, CA, USA) and 
isolated for positive selection with appropriate sized columns. OPCs were resuspended in 
OPCs medium (DMEM supplemented with 1% penicillin/streptomycin, 1% N2 supplement 
(Invitrogen), 2% B27 supplement (Invitrogen), 0.1% N-Acetyl-L-cysteine (Sigma-Aldrich), 
0.1% biotin (Sigma-Aldrich), 0.1% Trace Element B (Cellgro), and 0.1% Forskolin (Sigma-
Aldrich) and seeded into multi-well plates coated with poly-D-lysine at a density of 35000 
cells/cm
2
. Cells were grown at 37°C with 5% CO2 in the presence of growth factors (10 ng/ml 
ciliary neurotrophic factor (CNTF, Proteintech, USA), 20 ng/ml PDGFAA (Proteintech), 1 
ng/ml neurotrophin 3 (NT3, Proteintech)) and half of the medium was changed every two 
days maintaining the same final concentration of growth factors.  
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For the cell expansion experiment OPCs were grown in T75 flasks for 10 days in the 
presence of growth factors. After detaching with papain (2 U/ml) cells were sorted with 
A2B5-conjugated microbeads (see above) to ensure the use of undifferentiated OPCs. Cells 
were plated into multi-well plates coated with poly-D-lysine at a density of 35000 cells/cm
2
 
in the presence of growth factor-free OPC medium for four days. 
 
Immunohistochemistry and immunocytochemistry 
Mice were terminally anesthetized with sodium pentobarbital (Euthatal; 2 ml/kg; Rhône-
Mérieux) and transcardially perfused with 50 ml PBS followed by 50 ml of 4% 
paraformaldehyde (PFA) (Merck) dissolved in PBS pH 7.4. Spinal cords were post-fixed in 4% 
PFA overnight at 4°C, washed and then cryoprotected in PBS containing 25% sucrose and 
0.02% sodium azide at 4°C for at least 48h. Tissues were then embedded in OCT mounting 
medium (Thermo-Fisher) and stored at -80°C. Sections of the spinal cord (12 or 20 μm) were 
mounted onto positively charged glass slides (SuperFrost Plus; VWR) and sorted at -20°C. 
For colorimetric immonostaining the tissue’s peroxidase activity was quenched with 3% 
H2O2 in PBS containing 20% MetOH for 30 min at RT. Sections were then blocked with 
PBS/0.3% Triton-X 100 (PBST) containing 5% serum of appropriate species for 2h at RT, and 
incubated overnight at 4°C with primary antibodies diluted in PBST in the presence of 5% 
serum for non-tau antibodies. For fluorescence staining sections were incubated with the 
appropriate secondary antibody conjugated with Alexa fluorochromes (Life Technology) and 
nucleus dye Hoechst 33258 or DAPI (1 μg/ml) diluted in PBST for 2h at RT. Slides were 
mounted with FluorSafe (MerckMillipore) and fluorescence was visualized using a 
LeicaTMDM6000B fluorescence microscope and images were acquired with Leica LAS AF 
software. For colorimetric detection sections were incubated with the appropriate biotin-
conjugated secondary antibody (1:1000 in PBST) for 2h at RT followed by incubation with 
ABC kit (Vector) for 1h at RT. Staining was developed with 3,3 diaminobenzidine (Vector) 
and imaged with Olympus BX50 upright microscope. 
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 Supplementary figure 1. Late microgliosis in 5 month-old P301S-htau mice. Thoracic (T12-
T13) spinal cord sections (20 μm) from 5 month-old Wt and P301S-htau mice were 
immunostained for microglial markers (Iba1 and CD11b). Scale bars represent 100 μm, if not 
otherwise labelled. 
 
Supplementary figure 2. Comparison of P301S-htau and Wt mice lesion size. From the 
images used to quantify OPC and mature oligodendrocyte density, we calculated the 
average lesion area (see methods) of lysolecithin-injected P301S-htau and Wt mice. Data 
represent the mean ± SEM from eleven P301S-htau and ten Wt mice. Statistical difference 
between Wt and P301S-htau mice was calculated using unpaired t-test. 
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